Clinical Trials Directory

Trials / Completed

CompletedNCT05214508

Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease

Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease Patients and Its Relation to Severity and Acute Exacerbation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Beni-Suef University · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

The aim of this study is to estimate level of IL 6 in COPD patients and its relation to COPD severity and acute exacerbation.

Detailed description

1. A detailed clinical history was be carried out for every patient. In the clinical history, duration of COPD with a history of exacerbation and treatment will be elicited. History of the presence of risk factors such as smoking, exposure to fumes (biomass), and the presence of any other chronic disease were be inquired. 2. Thereafter, the detailed physical examination also had been carried out. 3. Pulmonary function test was performed by master screen NO : 781040 (care fusion) Measurements were obtained for FVC,FEV1,Ratio between them, PEF,FEF25%,FEF50% ,and FEF75% (The readings for FEV1 and Ratio were the ones included in the statistical analysis as indices for obstructive pattern of respiration). 4. Labs including Complete blood count, urea, and serum creatinine ,ESR was done for all patients 5. Exercise capacity by six minutes' walk test. 6. Dyspnea score by MMRC score. 7. Health state assessment by CAT score 3- 8- Determination of IL 6 serum levels. by sandwich enzyme-linked immunosorbent assay (ELISA). The detection range (0.2 ng/L- 8ng/L)

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTinterleukin 6assessment of serum IL-6 by ELISA

Timeline

Start date
2020-03-01
Primary completion
2020-11-01
Completion
2020-11-30
First posted
2022-01-28
Last updated
2022-01-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05214508. Inclusion in this directory is not an endorsement.